HVTN 111

A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,

Enrollment Opened

Objectives

-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

-To evaluate  immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

Trial design

Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.

Funder/Sponsor

NIH/DAIDS HVTN

 

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya 📢 new paper alert Results from @PanACEA_II showing that MBLA is better than MGIT TTD at predicting relapse in #TB p… https://t.co/e9KQFDEEJU
23hreplyretweetfavorite
NIMRMbeya RT @ifakarahealth: JOBS: Ifakara @ifakarahealth and the @SwissTPH invite applications from Tanzanians to fill 2 fully-funded three-year doc…
NIMRMbeya RT @SabiitiwWilber: Excellent north-south partnership in technology transfer. Sharing British science with the world @BritishCouncil @Chang
NIMRMbeya RT @SabiitiwWilber: We are delighted this week to host the delegation from NIMR-Mbeya Medical Research Centre TZ as part of strong collabor…
NIMRMbeya #unfoldingnewavenues Day 2️⃣ of the Tanzania Surgical Association AGM NIMR-Mbeya scientists conducted a workshop on… https://t.co/hdWg4cK0ij
© 2017 NIMR - Mbeya Medical Research Center